Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Post by u2bobon Jun 03, 2020 10:35am
188 Views
Post# 31106265

News....

News....Diagnos to provide AI tech to Labtician customers 2020-06-03 10:29 ET - News Release Mr. Polydor Strouthos reports DIAGNOS ANNOUNCES SIGNING OF STRATEGIC PARTNERSHIP AGREEMENT WITH LABTICIAN OPHTHALMICS, LEADING GLOBAL OPHTHALMOLOGY PRODUCT AND EQUIPMENT SUPPLIER Diagnos Inc. has signed a strategic partnership agreement with Labtician Ophthalmics Inc., a leading Toronto-based surgical eye care products and equipment company with customers across Canada who need Diagnos' artificial intelligence (AI) solution to monitor ocular health in diabetic patients. To increase its footprint and accelerate its growth, DIAGNOS has decided to work with organizations that are active in similar markets. This agreement will have the net effect of enabling access to new customers across Canada. As the world changes due to COVID-19, DIAGNOS needs to offer solutions that will help diabetic patients stay healthy. DIAGNOS' CARA solution allows close monitoring of the effects of medications used against the coronavirus, as well as changes seen in retinal microcirculation. The impact of COVID-19 on the vascular network has recently been identified and started to be monitored. DIAGNOS intends to be part of the solution destined to help professionals in their day-to-day screening of their patients."I am pleased to be working with the team at Labtician. Labtician brings a level of expertise and contacts that complement the DIAGNOS team of professionals. The addition of a sales and marketing team at Labtician will increase our reach in the market. Our growth strategy is to create partnerships in countries we want to access without having to invest in a significant work force of our own. In addition to companies like Labtician, our model will be to partner with other institutions in aligned medical verticals, such as in the diabetes and vascular sectors. Labtician is the perfect example of a partner that works closely with Canadian ophthalmology professionals dedicated to treating the effects of diabetes on the eyes. By treating their retinopathy, ophthalmologists are making sure patients do not lose their vision," explains Mr. Andre Larente, President of DIAGNOS. Mr. Polydor Strouthos, President of Labtician Ophthalmics stated "We are pleased to be working with DIAGNOS in addressing growing needs in monitoring of diabetic and hypertensive patients. For over 60 years, we've been world leaders in innovative eye care products, solutions, and resources for eye care professionals and their patients. Through our extensive network in eye care, we commercialize our high-quality ophthalmology products as well as those of our forward-thinking partner companies, in Canada and worldwide. We help companies through the complexities and nuances of Canadian and international markets, from prelaunch assistance and obtaining regulatory approval, to securing commercialization, and distribution channels". About DIAGNOS DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence ("AI") platform FLAIRE. Using the FLAIRE platform, DIAGNOS is able to build and further extend rapidly its applications such as CARA (Computer Assisted Retina Analysis). We seek Safe Harbor. 2020 Canjex Publishing Ltd. All rights reserved.
Bullboard Posts